Former IMPRS student Felipe Tapia researchs on Advance Gene Therapy Manufacturing
Scientists of the Bioprocess Engineering group receive a €1.1 Million Startup Grant for their project ContiVir.
On October 1, 2019, the spin-off project “ContiVir” officially started research and development activities at the Max Planck Institute (MPI) in Magdeburg. The two-year EXIST-Transfer of Research project is jointly funded by the European Union, the German Ministry for Economic Affairs and Energy, and the Max Planck Society. The project will focus on the development of a continuous manufacturing platform for commercially relevant viral gene therapy vectors. The grant is the result of the combined doctoral research of Dr.-Ing. Felipe Tapia and Dr.-Ing. Pavel Marichal, scientists of the Bioprocessing Engineering group headed by Prof. Dr.-Ing. Udo Reichl.
Gene therapies have shown the promise to become the next medical revolution for combating a wide variety of currently untreatable diseases. The most common delivery method for gene therapy are with viral vectors: genetically engineered viruses used as vehicles to introduce genetic material into the patient’s cells to replace defective genes by healthy ones. Currently, gene therapies cost from hundreds of thousands to millions of euros per patient.
A significant increase in the demand for viral gene therapy vectors is expected in the future, evidenced by both the market authorization of the first gene therapies in Europe and the US in recent years, and more than a thousand treatments in clinical phase. It is estimated that nowadays the demand for viral gene therapy vectors is five times higher than the current supply.
A major bottleneck in the supply of viral vectors is requirement for high dose titers and inefficient production techniques based on batch technologies meant for laboratory use. The latter are incredibly difficult to scale-up for commercial production and require large amounts of time and labor.
The EXIST-Transfer of Research project started aims to tackle some of the manufacturing issues described above by combining two disruptive new technologies established by the Bioprocess Engineering group of the MPI Magdeburg.
The first technology is a continuous tubular bioreactor developed by Felipe Tapia in the Upstream Processing team of PD. Dr. Yvonne Genzel. This bioreactor is the first fully continuous system for the production of virus particles and has a footprint twenty times smaller than current batch systems. Additionally, continuous processes have higher productivity than batch cultures for large volumes, consume less energy, and require less labor.
The viral vectors produced in the tubular bioreactor will be purified with a membrane-based chromatography technique developed by Pavel Marichal in the Downstream Processing team of Prof. Dr. Michael Wolff (now at the Technische Hochschule Mittelhessen, University of Applied Sciences in Giessen, Germany). The purification method, named steric exclusion chromatography (SXC), can be used to concentrate and purify a wide variety of viruses with high product yields using very similar process conditions supporting short process development. SXC uses low-cost materials and is easily scalable.
Both technologies will be integrated in a fully continuous manufacturing process that has the potential to meet the future demand of viral vectors to make gene therapies widely available to the general population. This manufacturing platform can also be used to support the production of viral vaccines in large quantities during pandemics, such as the current coronavirus outbreak that is considered by many countries as the worst crisis since World War 2.
The project will be carried out in the laboratories of the MPI Magdeburg and the Otto von Guericke University Magdeburg.
Image desription: ContiVir's continuous tubular bioreactor system for virus particles (model II).
Image source © ContiVir / Felipe Tapia